Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, following J&J's recent entry into STAT6 space ...

Regor Therapeutics' oral obesity drug RGT-075 shows 5% weight loss at 12 weeks in Phase 2a, trailing incretin pills from ...

Bayer's experimental Parkinson’s disease therapy made from stem cells will soon enter late-stage studies, marking a key test ...

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...

Radiopharmaceutical maker Lantheus Holdings plans to acquire Life Molecular Imaging for $350 million in a bid to build up its ...

Tune Therapeutics raises $175M Series B for epigenetic editing, with hepatitis B drug Tune-401 in the clinic. NEA, Yosemite, ...

Johnson & Johnson is considering an acquisition of CNS drugmaker Intra-Cellular Therapies, according to anonymous sources ...

NeurIPS, the biggest AI research conference, turned Vancouver’s convention center into a battleground for wooing AI talent.

Endpoints Weekly reports on iECURE's gene therapy success for OTC deficiency, FDA CDER director Patrizia Cavazzoni's departure, and Verdiva Bio's $411M launch with Sciwind assets.

Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, ...

Metsera files for IPO, developing GLP-1 drug MET-097i and other obesity treatments to compete with Eli Lilly and Novo Nordisk ...